Vascular endothelial and smooth muscle nitric oxide and prostanoid signaling (NO/Prostanoid signaling)

Vascular endothelial and smooth muscle nitric oxide (NO) and prostanoid signaling is a fundamental paracrine system that maintains vascular health by regulating blood flow and preventing clot formation. While often discussed as a single functional unit in vascular biology, this system comprises multiple distinct molecular targets rather than a single receptor or enzyme. The nitric oxide pathway involves the synthesis of NO by endothelial nitric oxide synthase (eNOS), which then diffuses into smooth muscle cells to activate soluble guanylate cyclase (sGC), leading to increased cGMP and vasodilation (StatPearls, 2023). Concurrently, the prostanoid pathway utilizes cyclooxygenase (COX) enzymes to produce prostacyclin (PGI2), which binds to IP receptors on smooth muscle and platelets to elevate cAMP levels, further promoting relaxation and inhibiting aggregation (PubMed, 2015). Together, these pathways ensure a balanced vascular environment; however, their impairment—often called endothelial dysfunction—is a primary driver of diseases like pulmonary arterial hypertension and atherosclerosis (PubMed, 2014). Therapeutic interventions target various nodes in this system, such as using sGC stimulators like riociguat or PDE5 inhibitors like sildenafil to enhance NO signaling, and prostacyclin analogs like epoprostenol to supplement prostanoid activity (NIH, 2022).

Other names

Endothelial-derived relaxing factor signalingNO-cGMP and PGI2-cAMP signalingVascular endothelial paracrine signalingArachidonic acid-nitric oxide pathway

Pharmacological agents modulate this system by increasing the bioavailability of nitric oxide, directly stimulating soluble guanylate cyclase to produce cGMP, inhibiting phosphodiesterase enzymes to prevent cyclic nucleotide degradation, or activating prostacyclin receptors to increase cAMP levels.